%0 Journal Article
%T Efficacy and Safety of Continuing Bevacizumab beyond Disease Progression plus Docetaxel in Patients with Non-Small Cell Lung Cancer: A Retrospective Analysis
%A Takashi Yokoi
%A Takayasu Kurata
%A Yoshitaro Torii
%A Yuichi Katashiba
%A Makoto Ogata
%A Naoko Murakami Satsutani
%A Maiko Niki
%A Noriko Inagaki Katashiba
%A Kayoko Nishimura Kibata
%A Shosaku Nomura
%J Advances in Lung Cancer
%P 8-15
%@ 2169-2726
%D 2015
%I Scientific Research Publishing
%R 10.4236/alc.2015.41002
%X <p class=\"MsoNormal\" style=\"text-align:justify;\">
	<span lang=\"EN-US\" style=\"font-size:10pt;font-family:Verdana, sans-serif;\">Background: Bevacizumab-based chemotherapy has
been shown to extend progression-free survival (PFS) of lung cancer, but its
effect on overall survival (OS) remains unclear. However, bevacizumab beyond
disease progression (BBP) significantly improved OS in patients with metastatic
colorectal cancer. Methods: Therefore, we retrospectively analysed 22 patients
with non-small cell lung cancer (NSCLC) who were treated with docetaxel plus
BBP at the Department of Thoracic Oncology, Kansai Medical University Hirakata
Hospital, between November 2009 and March 2013. Results: The response rate was
31.8% and the disease control rate was 86.4%. The median PFS was 4.5 months
(95% confidence interval [CI], 2.5 - 8.7 months) and the median OS was 17.2
months (95% CI, 8.5 - 25.9 months). Grade 3 and 4 adverse events included
leukocytopenia (68.2%), neutropenia (77.3%), fatigue (9.1%), proteinuria
(9.1%), febrile neutropenia (4.5%), anemia (4.5%), and anorexia (4.5%).
Conclusion: Docetaxel plus BBP was found to be generally well tolerated and
effective.</span> 
</p>
%K Bevacizumab beyond Disease Progression
%K NSCLC
%K Second-Line Chemotherapy
%K Docetaxel
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=55048